UndisclosedStrategic acquisitionHealthcare & Life SciencesCompleted
Alcon acquires Neurotech and MacTel treatment ENCELTO
Geneva-based eye care company Alcon has acquired Neurotech and its product ENCELTO, the only FDA-approved treatment for macular telangiectasia type 2. Terms were not provided in the announcement excerpt.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Get healthcare deals like this every morning
The day's biggest deals in five minutes. Free, with no paywalled links.